rezpegaldesleukin

News

Nektar eyes pivotal trials for eczema drug cast off by Lilly

Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis.

News

Nektar says Lilly got it wrong on eczema drug rezpeg

Nektar Therapeutics says that Eli Lilly made a big mistake when it reported data on a pair of phase 1b trials of its rezpegaldesleukin drug in atopic dermatitis and psoria

News

After setback, Rhythm gets good news on Imcivree from FDA

Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks